close 74% de inversores minoristas pierde dinero cuando opera con CFDs en este proveedor. Las inversiones conllevan riesgos y no son adecuadas para todos los inversores. Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento. 74% de inversores minoristas pierde dinero cuando opera con CFDs en este proveedor. Debes considerar si comprendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
BuscarBuscar
Change languageEspañol
Dashboard

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

LLY

911.65

+0.96%↑

JNJ

235.8

+0.14%↑

ABBV

205.01

+0.38%↑

NVS

147.58

+1.16%↑

AZN

184.25

+0.48%↑

Inicio・Lista de Acciones・VIRIDIAN THERAPEUTICS INC
Search

VIRIDIAN THERAPEUTICS INC

Cerrado

SectorSanidad

27.49 2.5

Compra Fuerte

Precios actualizados 23 mar 2026, 19:59 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

26.82

Máximo

28.21

Métricas clave

By Trading Economics

Ingresos

-86M

-120M

Ventas

-70M

132K

BPA

-1.08

Margen de beneficios

-91,178.03

Empleados

252

EBITDA

-80M

-114M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+50.98% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

261M

2.9B

Apertura anterior

24.99

Cierre anterior

27.49

Noticias sobre sentimiento de mercado

By Acuity

20%

80%

40 / 350 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

12 / 13.14 Soporte y Resistencia

VIRIDIAN THERAPEUTICS INC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 mar 2026, 23:47 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

DJ

Leer

23 mar 2026, 22:55 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

DJ

Leer

23 mar 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

DJ

Leer

23 mar 2026, 23:59 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

DJ

Leer

23 mar 2026, 23:59 UTC

Charlas de Mercado

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

DJ

Leer

23 mar 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

DJ

Leer

23 mar 2026, 23:37 UTC

Charlas de Mercado

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

DJ

Leer

23 mar 2026, 22:42 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Global Equities Roundup: Market Talk

DJ

Leer

23 mar 2026, 22:42 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

DJ

Leer

23 mar 2026, 22:40 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

DJ

Leer

23 mar 2026, 22:23 UTC

Charlas de Mercado

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

DJ

Leer

23 mar 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

DJ

Leer

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

DJ

Leer

23 mar 2026, 22:21 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

DJ

Leer

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

DJ

Leer

23 mar 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

DJ

Leer

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

DJ

Leer

23 mar 2026, 22:19 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

DJ

Leer

23 mar 2026, 22:18 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

DJ

Leer

23 mar 2026, 22:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

DJ

Leer

23 mar 2026, 22:08 UTC

Charlas de Mercado

Ebos Needs to Reset Its Gearing Targets -- Market Talk

DJ

Leer

23 mar 2026, 21:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

DJ

Leer

23 mar 2026, 21:42 UTC

Charlas de Mercado

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

DJ

Leer

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

DJ

Leer

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

DJ

Leer

23 mar 2026, 21:32 UTC

Ganancias

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

DJ

Leer

23 mar 2026, 21:10 UTC

Noticias de Eventos Importantes

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

DJ

Leer

23 mar 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

DJ

Leer

23 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

DJ

Leer

23 mar 2026, 20:50 UTC

Charlas de Mercado
Ganancias
Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

DJ

Leer

Comparación entre iguales

Cambio de precio

VIRIDIAN THERAPEUTICS INC previsión

Precio Objetivo

By TipRanks

50.98% repunte

Estimación a 12 Meses

Media 41.7 USD  50.98%

Máximo 50 USD

Mínimo 29 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para VIRIDIAN THERAPEUTICS INC Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

11

Comprar

1

Mantener

0

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para VIRIDIAN THERAPEUTICS INC Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

12 / 13.14Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Medio plazo

Bearish Evidence

All events are bearish.

Largo Plazo

Strong Bearish Evidence

All events are bearish.

Sentimiento

By Acuity

40 / 350 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Otras acciones del sector

LLY

Eli Lilly and Co.

911.65

↑ +0.96%

JNJ

Johnson and Johnson

235.8

↑ +0.14%

ABBV

AbbVie Inc

205.01

↑ +0.38%

NVS

Novartis AG

147.58

↑ +1.16%

AZN

AstraZeneca PLC

184.25

↑ +0.48%
help-icon Live chat